**Mazurek_Supplemental Figure 2**

**A**

**AND-1**

- Plasmid stability ratio vs. shRNA

**B**

**DDX5**

- Plasmid stability ratio vs. shRNA

**C**

**NCAP-G2**

- Plasmid stability ratio vs. shRNA
Mazurek_Supplemental Figure 3

A

B

Plasmid stability ratio

shRNA

DDX17

Beta-Actin

Luciferase

mi203

V2HS_238845
V2HS_203066
V2HS_203274

1.00 0.25 0.10
Mazurek_Supplemental Figure 4

A

\[ \text{DDX5si2053} \]

- \( G1 \) - 57.5%
- \( S \) - 22.8%
- \( G2/M \) - 19.4%

\[ \text{EBNA1si1666} \]

- \( G1 \) - 49.5%
- \( S \) - 28.5%
- \( G2/M \) - 21.7%

B

\[ \text{DDX5si2008} \]

- 7.3%

\[ \text{DDX5si2053} \]

- 13.8%

\[ \text{EBNA1si1666} \]

- 25.8%
A

B

C

Mazurek_Supplemental Figure 5

Relative abundance of DDX5 transcript

Relative abundance of GAPDH transcript

DDX5

DDX5mi2008

DDX5mi2053

RenLucmi713

LPC-DDX5

LPC-Empty

RLucmi713

D5mi2008

D5mi2053

D5

E

DDX5

D5

E

LPC-DDX5

LPC-Empty

DDX5
Mazurek_Supplemental Figure 6

A

24hrs post-transfection

Percent of cell population

G1  S  G2/M

B

48hrs post-transfection

Percent of cell population

G1  S  G2/M

C

siRNA: D5  E  D5  E  D5  E

DDX5

RB

Beta-Actin
Mazurek Supplemental Figure 9

A

DDX5mi2008

Empty vector

B

Trastuzumab concentration (µg/mL)

Absorbance

C

Trastuzumab concentration (µg/mL)

Absorbance (normalized to untreated)
A

MDA-MB-453

SKBR3

EFM19

ZR-75-1

B

EVSA-T

HCC1143

Hs578t